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To examine fatty acid accumulation and its toxic eﬀects in cells, we analyzed skin ﬁbroblasts from six patients with mitochondrial
trifunctionalproteindeﬁciency,whohadabnormalitiesinthesecondthroughfourthreactionsinfattyacidβ-oxidationsystem.We
found free fatty acid accumulation, enhanced three acyl-CoA dehydrogenases, catalyzing the ﬁrst reaction in the β-oxidation sys-
tem and being assumed to have normal activities in these patients, and PPARα activation that was conﬁrmed in the experiments
usingMK886,aPPARαspeciﬁcantagonistandfenoﬁbrate,aPPARαspeciﬁcagonist.Thesenovelﬁndingssuggestthatthefattyacid
accumulation and the resulting PPARα activation are major causes of the increase in the β-oxidation ability as probable compen-
sation for fatty acid metabolism in the patients’ ﬁbroblasts, and that enhanced cell proliferation and increased oxidative stress
due to the PPARα activation relate to the development of speciﬁc clinical features such as hypertrophic cardiomyopathy, slight
hepatomegaly, and skeletal myopathy. Additionally, signiﬁcant suppression of the PPARα activation by means of MK886 treatment
is assumed to provide a new method of treating this deﬁciency.
1.Introduction
The presence of an excessive level of fatty acids may cause
signiﬁcant toxicity in many organs and tissues. We recently
examined the close relation between fatty acid toxicity and
peroxisome proliferator-activated receptor (PPAR) func-
tions. In some of our experiments, acute kidney injury was
induced by albumin-overload nephropathy, in which PPARα
protected proximal tubular cells from acute toxicity induced
by fatty acids bound to albumin [1]; furthermore, pretreat-
ment with low-dose ﬁbrates protected against the fatty-
acid-induced renal tubule toxicity by counteracting PPARα
deterioration [2]. In our other experiments, hepatic steatosis
and hepatocellular carcinoma in hepatitis C virus core pro-
tein transgenic mice were caused through fatty-acid-induced
PPARα activation [3, 4]. These in vivo experiments provided
important results concerning fatty acid toxicity at the organ
and tissue levels; however, the degree of the toxicity diﬀered
greatly, even among the same types of cells. We, therefore,
undertook several experiments using cultured cells to eluci-
date the detailed mechanisms in the cell toxicity. We adopted
ﬁbroblasts from patients having a certain abnormality in the
mitochondrial fatty acid β-oxidation system.
Trifunctional protein (TP), catalyzing fatty acid β-oxida-
tion in mitochondria, is a multienzyme complex com-
posed of four molecules of the α-subunit containing the
enoyl-CoAhydrataseand3-hydroxyacyl-CoAdehydrogenase
domains and four molecules of the β-subunit contain-
ing the 3-ketoacyl-CoA thiolase domain. An inborn error
of this enzyme complex can cause sudden infant death2 PPAR Research
syndrome, hepatomegaly accompanying fat accumulation,
hepatic encephalopathy, skeletal myopathy, or hypertrophic
cardiomyopathy with rather high frequency. This deﬁciency
is classiﬁed into two diﬀerent phenotypes: one represents the
existence of both subunits and the lack of only the 3-hyd-
roxyacyl-CoA dehydrogenase activity and the other repre-
sents the absence of both subunits and the lack of the three
activities, although the clinical features of these two phe-
notypes are similar [5–7].
2.MaterialsandMethods
2.1. Chemicals. MK886, a PPARα-speciﬁc antagonist [8]a n d
fenoﬁbratewereobtainedfromWakoPureChemical(Osaka,
Japan) and Sigma Chemical Company (St. Louis, MO, USA),
respectively.
2.2.SourceoftheCellsandCultureMethod. Thecasehistories
of the TP patients were reported elsewhere [5–7]. Skin
ﬁbroblastswerecollectedfromthepatients[5,9,10]andcul-
tured in the medium containing Dulbecco’s modiﬁed Eagle’s
medium, 10% (v/v) fetal calf serum, 0.1mM nonessential
amino acids, 1 X antibiotic-antimycotic solution (Invitrogen
Life Technologies Corp., Carlsbad, CA, USA) and 4.5mg D-
glucose/mL.
2.3.Acyl-CoADehydrogenaseActivity. About1-2mgofﬁbro-
blastswassuspendedin150μLofsolutioncontaining67mM
potassium phosphate (pH 7.5), 200mM sodium chloride,
and 0.6% (w/v) Triton X-100. The suspension was gently
sonicated, and the solution was centrifuged at 3,000×gf o r
5min. Fifty μL of the supernatant fraction was mixed with a
solution containing 67mM potassium phosphate (pH 7.5),
40–50μM palmitoyl-CoA (or octanoyl-CoA), and 0.4μM
electron transfer ﬂavoprotein, in a ﬁnal volume of 1.5mL.
The mixture without the electron transfer ﬂavoprotein was
preincubated for 2min at 37◦C with gentle bubbling of nit-
rogen gas to exclude oxygen. The reaction was started by
addition of electron transfer ﬂavoprotein, and run under nit-
rogen gas. Electron transfer ﬂavoprotein reduction was mea-
sured by using a ﬂuorometer (Hitachi F-2000) with excita-
tion at 342nm and emission at 496nm [11]. The activities in
ﬁbroblasts were also measured by the method coupling with
ferricenium ion [12] in order to conﬁrm them.
2.4. Immunoblot Analysis. Protein concentrations were mea-
sured colorimetrically with a BCA Protein Assay kit (Pierce
Biotechnology Inc., Rockford, IL, USA). Whole-cell lysates
(60μg protein) were subjected to 10% SDS-polyacrylamide
gel electrophoresis [13]. After electrophoresis, the proteins
were transferred to nitrocellulose membranes, which were
incubated with the primary antibody and then with alkaline
phosphatase-conjugated goat anti-rabbit IgG. Antibodies
against VLCAD, LCAD, and MCAD were described previ-
ously[14,15].Thebandofactinwasusedastheloadingcon-
trol. Band intensities were measured densitometrically, nor-
malized to those of actin, and then expressed as fold changes
relative to the averaged value of the three control ﬁbroblasts.
2.5. Analysis of mRNA. Total RNA was extracted using an
RNeasy Mini Kit (QIAGEN, Hilden, Germany), and samples
of 2μg of RNA were reverse transcribed using oligo-dT
primers and SuperScript II reverse transcriptase (Invitrogen
L i f eT e c h n o l o g i e sC o r p . ) .L e v e l so fm R N Aw e r eq u a n t i ﬁ e d
by real-time polymerase chain reaction using a SYBR Premix
Ex Taq II (Takara Bio, Otsu, Japan) on a Thermal Cycler
Dice TP800 system (Takara Bio) [3, 16]. Speciﬁc primers
were designed by Primer Express software (Applied Bio-
systems, Foster City, CA, USA): 5 -GAGCCACGGACT-
TCCAGATA-3  and 5 -GCATTCATCTGTCACCTTCCA-3 
for the VLCAD gene; 5 -TCACTCAGAATGGGAGAA-
AGC-3  and 5 -CTCCAATTCCACCAAGATGCT-3  for the
LCAD gene; 5 -TAACCAACGGAGGAAAAGCT-3  and 5 -
CTGCTTCCACAATGAATCCA-3  for the MCAD gene;
5 -GTGAAATCGGGACCCATAAG-3 and5 -CGATGGTTG-
TCCATTTTGAG-3  for the peroxisomal acyl-CoA oxidase
gene; 5 -CCATTCGATCTCACCAAGGT-3  and 5 -GGA-
TTCCGGTTTAAGACCAGTT-3  for the catalase gene;
5 -GGAGGGAGCTGACTGATACACT-3  and 5 -TCAGCA-
GGTTGGCAATCTC-3  for the c-Fos gene; 5 -GGACTA-
TCCTGCTGCCAAGA-3  and 5 -CTGGTGCATTTTCGG-
TTGTT-3  for the c-Myc gene; 5 -CACTGGTGGTCC-
ATGAAAAAG-3  and 5 -ACTTCCAGCGTTTCCTGTCT-3 
for the Cu, Zn-superoxide dismutase gene; 5 -CCG-
AGAAGCTGTGCATCTACA-3  and 5 -GGTTCCACTTGA-
GCTTGTTCA-3  for the cyclin D1 gene; 5 -TGTATG-
GAAGAGCCCAGATTC-3  and 5 -GCACAGTACAGGCAC-
AAAGGT-3  for the NADPH oxidase 4 gene; 5 -GGC-
GTGAACCTCACCAGTAT-3  and 5 -GCGTTATCTTCG-
GCCCTTAG-3  for the proliferating cell nuclear antigen
gene; 5 -CCTCAAGATCATCAGCAATGC-3  and 5 -GGT-
CATGAGTCCTTCCACGAT-3  for the GAPDH gene. The
mRNA levels of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were used as an internal control. Measurements
of mRNA levels were normalized to those of GAPDH and
then expressed as fold changes relative to the averaged value
of the three control ﬁbroblasts.
2.6. Assays for DNA Binding Activity of PPARs. The DNA-
binding activity of PPARα,P P A R β,a n dP P A R γ was deter-
mined using the PPARα,P P A R β,a n dP P A R γ Transcription
Factor Assay kits (Cayman Chemical, Ann Arbor, MI, USA)
[17–19], respectively. These assays are based on an enzyme-
linked immunosorbent assay using PPAR response element-
(PPRE-) immobilized microplates and speciﬁc PPAR anti-
bodies, thus oﬀering similar results to those from the con-
ventional radioactive electrophoretic mobility shift assay.
DNA-binding assays were carried out according to the
manufacturer’s instructions using whole-cell lysates (100μg
protein). Results are expressed as fold changes relative to the
averaged value of the three control ﬁbroblasts.
2.7. Analyses of TG and FFA. To determine the content of
triglycerides (TGs) and free fatty acids (FFAs), lipids were
extracted according to a method reported by Hara and Radin
[20]. TG and FFA were measured with Triglyceride E-test kitPPAR Research 3
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Figure 1: Acyl-CoA dehydrogenase activity and FFA/TG contents in ﬁbroblasts. Assay methods were, respectively, described in Section 2.( a )
Indicates palmitoyl-CoA (open bar, C16) and octanoyl-CoA (closed bar, C8) dehydrogenase activities, respectively. (b) Indicates FFA (open
bar) and TG (closed bar) contents, respectively. P1–P6, individual patient’s ﬁbroblast; C1–C3, individual control ﬁbroblast; P, means ± SD
in six patients’ ﬁbroblasts; C, means ± SD in three control ﬁbroblasts. ∗P<0.05 versus controls.
andanNEFAC-testkit(WakoPureChemical,Osaka,Japan),
respectively.
2.8. Statistical Analysis. A l ld a t aa r ee x p r e s s e da sm e a n±
standard deviation (SD). Statistical analysis was performed
using one-way ANOVA with Bonferroni correction (SPSS
Statistics17.0;SPSSInc,Chicago,IL,USA).Correlationcoef-
ﬁcients were calculated using Spearman’s rank correlation
analysis. A probability value of less than 0.05 was considered
to be statistically signiﬁcant.
3. Results
3.1. Acyl-CoA Dehydrogenase Activity and the Content of
TG/FFA in Fibroblasts. Six strains of skin ﬁbroblasts were
prepared from the individual TP patients, as well as the three
strains from the healthy adult men as described in Section 2.
The reproductive rate of these ﬁbroblasts was similar in
all strains. TP deﬁciency is based on abnormalities in the
second through fourth reactions in the mitochondrial fatty
acid β-oxidation system; therefore, acyl-CoA dehydrogenase,
catalyzing the ﬁrst reaction in the β-oxidation system, was
assumed to be normal in the patients’ ﬁbroblasts. Addition-
ally, increased levels of FFA/TG due to the impaired β-oxi-
dation ability in these ﬁbroblasts were expected. Thus, these
parameters were analyzed ﬁrst. Palmitoyl-CoA and octanoyl-
CoAdehydrogenaseactivitiesinthepatients’ﬁbroblastswere
1.72- and 1.64-fold higher than those in the control ﬁbro-
blasts,respectively,(Figure 1(a)).FFAcontentinthepatients’
ﬁbroblasts was 3.2-fold higher than that in the control
ﬁbroblasts, while TG levels were similar in both ﬁbroblasts.
These FFA and TG levels were much lower than those in
human serum (Figure 1(b)).
3.2. Expression of Three Acyl-CoA Dehydrogenases. Palmi-
toyl-CoA and octanoyl-CoA dehydrogenation are catalyzed
by three forms of acyl-CoA dehydrogenase; therefore, their
expression levels were examined. The protein levels of
VLCAD, LCAD, and MCAD in the patients’ ﬁbroblasts were
1.55-, 2.15-, and 1.97-fold higher than those in the control
ﬁbroblasts, respectively, (Figure 2(a)). The mRNA contents
of VLCAD, LCAD, and MCAD in the patients’ ﬁbroblasts
were 2.00-, 2.92-, and 2.63-fold higher than those in the
control ﬁbroblasts, respectively, (Figure 2(b)). These data
were consistent with the observations shown in Figure 1(a).
The simultaneous increases in the expression levels of the
three forms of acyl-CoA dehydrogenase strongly suggested
the presence of PPARα activation in the patients’ ﬁbroblasts,
since the three forms are known as PPARα target gene
products[15].Thepr esenc eofPP ARαactivationwasthereby
examined in detail.
3.3. Assays for DNA-Binding Activity of PPARs. Immunoblot
analysis using whole-cell lysates from the ﬁbroblasts and
speciﬁc antibodies was performed and provided very faint
bands for PPARβ and no bands for PPARα and PPARγ.
mRNA analysis was also done as described in Section 2,a n d
indicated that the PPARα, β,a n dγ mRNAs were 10−6∼10−4
levels for GAPDH mRNA in the ﬁbroblasts, meaning that
the data from the immunoblot and mRNA analyses were
unreliable for detecting PPAR activation. The PPRE-binding
assay was then done, which demonstrated an increase of
PPRE-binding activity only for PPARα in the whole-cell
lysates from the patients’ ﬁbroblasts (Figure 3). These data
supported the presence of PPARα activation in the patients’
ﬁbroblasts.
3.4. Treatments with MK886 and Fenoﬁbrate. To conﬁrm the
appearance of PPARα activation in the patients’ ﬁbroblasts,
the ﬁbroblasts were treated with MK886, a PPARα-speciﬁc
antagonist and fenoﬁbrate, a PPARα speciﬁc agonist, respec-
tively.TheexpressionlevelofMCAD,arepresentativePPARα4 PPAR Research
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Figure 2: Expression levels of three Species of acyl-CoA dehydrogenase. Assay methods were, respectively, described in Section 2.( a )S h o w s
relative quantiﬁcation of expression levels of three acyl-CoA dehydrogenases. Upper panel indicates protein bands in immunoblot analysis.
The band of actin was used as the loading control. Lower panel indicates relative protein amounts obtained by immunoblot and
densitometric analyses. (b) Shows relative mRNA expression. Open bar, VLCAD; gray bar, LCAD; closed bar, MCAD. P1–P6, individual
patient’sﬁbroblast;C1–C3,individualcontrolﬁbroblast;P,means ±SDinsixpatients’ﬁbroblasts;C,means±SDinthreecontrolﬁbroblasts.
∗P<0.05, versus controls.
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Figure 3: PPRE-binding activity. Assay methods were described in
Section 2.O p e nb a r ,P P A R α;g r a yb a r ,P P A R β; closed bar, PPARγ.
P1–P6, individual patient’s ﬁbroblast; C1–C3, individual control
ﬁbroblast; P, means ± SD in six patients’ ﬁbroblasts; C, means ± SD
in three control ﬁbroblasts. ∗P<0.05, versus controls.
target gene product, was investigated. In the patients’ ﬁbro-
blasts, the MK886 treatment evidently reduced MCAD
expression both in the protein and mRNA levels, and the
fenoﬁbrate treatment left this expression unchanged. In
the control ﬁbroblasts, the MK886 treatment did not aﬀect
this expression, and the fenoﬁbrate treatment increased it
both in the protein and mRNA levels (Figure 4). These
data demonstrated that a considerable level of PPARα acti-
vation constitutively functioned in the patients’ ﬁbroblasts.
4. Discussion
This study demonstrated the occurrence of FFA accumula-
tion, increased palmitoyl-CoA and octanoyl-CoA dehydro-
genase activities, coordinated enhancement in the expression
of three acyl-CoA dehydrogenases, a signiﬁcant increase of
PPRE-binding activity only for PPARα, and reduced MCAD
e xpr essionasar esultofPP ARα-speciﬁcantagonisttreatment
in all of the ﬁbroblasts from six patients with TP deﬁciency
who had abnormalities in the second through fourth reac-
tions in the mitochondrial fatty acid β-oxidation system.
These results demonstrated that a considerable level of
PPARα activation constitutively functioned in the patients’
ﬁbroblasts, in which FFA seemed to act as endogenous lig-
ands toward PPARα as reported elsewhere [21–23]. FFA
seems to work not toxically but protectively in the patients’
ﬁbroblasts, since the FFA accumulation and the resulting
PPARα activation probably compensated for the impaired
fatty acid metabolism in the patients’ ﬁbroblasts. It would be
interesting to investigate whether this compensation appears
in the patients’ liver and heart, where considerable increases
of TG/FFA and much higher levels of PPARα expression are
expected [3, 24, 25]. From this viewpoint, the results ob-
tained by using the patients’ ﬁbroblasts in the current study
are useful for understanding the PPARα function.
This PPARα activation might induce cell proliferation in
the patients’ ﬁbroblasts. To examine it, the mRNA levels
withsev e ralo nc og e nep r od uctsandc ellcy c ler egulat o r sw e r e
analyzed. The mRNA levels in the patients’ ﬁbroblasts were
2.5±0.5-foldforc-Fos,3.0±0.6-foldforc-Myc,2.4±0.7-fold
for cyclin D1, and 2.1±0.3-fold for proliferating cell nuclearPPAR Research 5
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Figure 4: Eﬀects of the MK886 or fenoﬁbrate treatment on MCAD expression. The ﬁbroblasts were plated in dishes and allowed to grow
to 80% conﬂuence. MK886 (30μM ﬁnal concentration) and fenoﬁbrate (200μM ﬁnal concentration) were added to cell culture media,
respectively. Both chemicals were dissolved in DMSO, and the ﬁnal concentration of DMSO in media was maintained at 0.05% (v/v) in all
cases. After 6h, ﬁbroblasts were harvested and used to analyze MCAD expression. (a) Shows relative quantiﬁcation of expression level of
MCAD protein. Upper panel indicates protein bands in immunoblot analysis. The band of actin was used as the loading control. Protein
bands of two patients (P1 and P2) and a control (C1) are shown due to space limitation. Lower panel indicates relative protein amounts
obtained by immunoblot and densitometric analyses. (b) Shows relative mRNA expression. Open bar, no treatment; gray bar, MK886
treatment; closed bar, fenoﬁbrate (FF) treatment. P1–P6, individual patient’s ﬁbroblast; C1–C3, individual control ﬁbroblast; P, means ± SD
in six patients’ ﬁbroblasts; C, means ± SD in three control ﬁbroblasts. ∗P<0.05, versus controls; #P<0.05, no treatment versus MK886 or
fenoﬁbrate treatment.
antigen, which are all known as possible PPARα target
gene products [3], when compared with those in the con-
trol ﬁbroblasts. These results suggest the presence of pro-
moted cell proliferation in the patients’ ﬁbroblasts, which
appears to be helpful for elucidating the mechanisms of
hypertrophic cardiomyopathy and hepatomegaly that occur
inTP-deﬁcientpatients.Additionally,thisworkdescribedin-
creased oxidative stress in the patients’ ﬁbroblasts. Biochem-
ical analysis measuring 4-hydroxyalkenals and malondialde-
hyde with the use of an LPO-586 kit demonstrated 2.2 ± 0.2
times greater lipid peroxides contents in the patients’ ﬁbrob-
lasts than in the control ﬁbroblasts, implying enhanced levels
of oxidative stresses in the former ﬁbroblasts. This ﬁnding
was consistent with the results of mRNA analysis: the mRNA
levelsinthepatients’ﬁbroblastswere2.7±0.3-foldforperox-
isomal acyl-CoA oxidase, which is known as a representative
PPARαtargetgeneproduct[3,15],1.3±0.4-foldforcatalase,
0.9±0.3-foldforCu,Zn-superoxidedismutase,and1.1±0.4-
fold for NADPH oxidase 4, when compared with those in the
controlﬁbroblasts.This increased oxidative stress might help
to elucidate the mechanisms of skeletal muscle weakness and
hepatic encephalopathy, which occur in many TP-deﬁcient
patients. The FFA accumulation and the resulting PPARα
activation seem to exert not protective but toxic eﬀects on
the patients’ ﬁbroblasts, since the activation aggravates intra-
cellular circumstances by increasing oxidative stresses and
promoting cell proliferation, which counteracts the protec-
tive role mentioned above of compensating for the impaired
fatty acid metabolism in the patients’ ﬁbroblasts.
Additionally, this research pointed out the signiﬁcant
suppression of the PPARα activation by the MK886 treat-
ment, which might be useful to eliminate the toxic eﬀects
of the activation. Thus, the MK886 treatment together
with the administration of glucose or sucrose to supply
energy might oﬀer a new method for treating this deﬁ-
ciency.
By the way, short-chain (SCAD), medium-chain, long-
chain, and very-long-chain acyl-CoA dehydrogenases are
known to catalyze the ﬁrst reaction in the mitochondrial β-
oxidation system. Among the four isozymes, the presence of
SCAD, MCAD, and VLCAD deﬁciencies has been reported.
Patients with SCAD deﬁciency occasionally represented ske-
letal muscle weakness and developmental delay [26, 27], and
those with MCAD deﬁciency frequently exhibited fasting
intolerance and hypoketotic hypoglycemia [28, 29], which
is rather dissimilar to the clinical features of patients with
TP deﬁciency. On the other hand, patients with VLCAD
deﬁciency frequently presented with fasting coma, skeletal
muscleweakness,skeletalmyopathy,hypertrophiccardiomy-
opathy,cardiomegaly,andslighthepatomegalywithfataccu-
mulation[30–32],conditionswhicharesimilartotheclinical
features of patients with TP deﬁciency. This similarity may
depend on the PPARα activation induced by accumulated
long-chain fatty acids and their derivatives. A future study
using ﬁbroblasts from patients with VLCAD deﬁciency is
expected to conﬁrm the mechanisms mentioned in this
paper.6 PPAR Research
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